Fig. 1

The Nanostring nSolver advanced analysis for the targeted gene expression, pathway signatures, and immune cell profiles between BM-LUAD and BCBM using nCounter PanCancer IO 360™ Panel. a Experimental set-up of targeted gene expression profiling (Nanostring nCounter PanCancer IO360 panel, n = 770 genes) and protein expression (GeoMx DSP) of BM-LUAD (n = 11) and BCBM (n = 11) from FFPE tissue samples. b Volcano plot indicating differentially expressed genes between BCBM and BM-LUAD (adj. p ≤ 0.05). c Heatmap of normalized differentially expressed genes between BCBM and BM-LUAD (absolute fold change ≥ 1; adj. p ≤ 0.05). The scaling of the heatmap is based on each gene. d Box plots of nCounter PanCancer IO 360™ biological signatures representing the set of pathway scores upregulated in each brain metastasis group (* adj. p ≤ 0.05; ** adj. p ≤ 0.01). e Box plots of immune cell scores acquired pursuant to the tumor location and showing higher levels of CD45 + cells notably T cells and cytotoxic cells in BM-LUAD (* adj. p ≤ 0.05; ** adj. p ≤ 0.01)